Drug intelligence / Profile preview

disitamab vedotin + trastuzumab

Development stage: Preclinical
Lead developer: RemeGen
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A combination therapy consisting of disitamab vedotin (RC48), an antibody-drug conjugate targeting HER2, and trastuzumab, a monoclonal antibody also targeting HER2. Disitamab vedotin contains a novel humanized anti-HER2 antibody conjugated to monomethyl auristatin E (MMAE) via a protease-cleavable linker. The combination is being investigated for treatment of HER2-positive cancers, particularly in cases resistant to standard therapies.

Brand names: AidixiHerceptin
Other names: hertuzumab + trastuzumab

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on disitamab vedotin + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on disitamab vedotin + trastuzumab.

Explore the full profile